ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ACRS vs STTK // RETURN ON INVESTED CAPITAL (ROIC)

Aclaris Therapeutics Inc. (NASDAQ) VS. Shattuck Labs Inc. (NASDAQ) • 15-METRIC TALLY: ACRS 4 — STTK 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ACRS VS. STTK) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ACRS STTK SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 73.30% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) ACTIVE -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -8.04% -6.96% -1.08 STTK /fcf-yield <GO>
Operating Margin -60.00% -60.00% 0.00 TIE /operating-margins <GO>
Net Profit Margin -60.00% -60.00% 0.00 TIE /net-margins <GO>
Revenue Growth (YoY) -58.20% -65.00% +6.80 ACRS /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 26.00 -25.80 STTK /balance-sheet <GO>
Piotroski F-Score Quality 4/9 3/9 +1.00 ACRS /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 45.5 43.2 +2.34 ACRS /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $587.3M $574.1M $13.2M ACRS /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ACRS REV STTK REV ACRS GROSS % STTK GROSS % ACRS FCF STTK FCF
FY 2025 $7.8M $1.0M 73.3% — -$47.2M -$40.0M
FY 2024 $18.7M $5.7M 85.1% — -$20.2M -$60.6M
FY 2023 $31.2M $1.7M — — -$78.3M -$81.2M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ACRS // BETA —
STTK // BETA —